GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 103 filers reported holding GRITSTONE ONCOLOGY INC in Q2 2021. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85,776 | -70.4% | 49,870 | -58.3% | 0.00% | – |
| Q2 2022 | $290,000 | -13.2% | 119,645 | +47.6% | 0.00% | – |
| Q1 2022 | $334,000 | -48.0% | 81,064 | +62.3% | 0.00% | – |
| Q4 2021 | $642,000 | -70.1% | 49,932 | -74.9% | 0.00% | -100.0% |
| Q3 2021 | $2,149,000 | -71.2% | 198,924 | -75.6% | 0.00% | -75.0% |
| Q2 2021 | $7,451,000 | +3644.2% | 816,059 | +3772.2% | 0.00% | – |
| Q1 2021 | $199,000 | -61.5% | 21,075 | -84.0% | 0.00% | – |
| Q4 2020 | $517,000 | +27.3% | 131,363 | -14.2% | 0.00% | – |
| Q3 2020 | $406,000 | -51.1% | 153,086 | +22.3% | 0.00% | -100.0% |
| Q2 2020 | $831,000 | +151.1% | 125,167 | +120.2% | 0.00% | – |
| Q1 2020 | $331,000 | -35.5% | 56,849 | -0.9% | 0.00% | – |
| Q4 2019 | $513,000 | +27.6% | 57,357 | +22.7% | 0.00% | – |
| Q3 2019 | $402,000 | -7.2% | 46,748 | +19.7% | 0.00% | – |
| Q2 2019 | $433,000 | +13.6% | 39,070 | +36.0% | 0.00% | – |
| Q1 2019 | $381,000 | -15.0% | 28,729 | -1.1% | 0.00% | – |
| Q4 2018 | $448,000 | – | 29,056 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,102,929 | $18,059,047,000 | 4.95% |
| Svennilson Peter | 3,102,934 | $18,059,000 | 2.29% |
| Casdin Capital, LLC | 2,270,000 | $13,211,000 | 1.40% |
| FRAZIER MANAGEMENT LLC | 2,061,758 | $11,999,000 | 1.36% |
| Redmile Group, LLC | 3,068,194 | $17,857,000 | 0.50% |
| Alphabet Inc. | 929,022 | $5,407,000 | 0.36% |
| Bleichroeder LP | 169,039 | $984,000 | 0.26% |
| Leap Investments LP | 14,400 | $84,000 | 0.12% |
| DAFNA Capital Management LLC | 50,000 | $291,000 | 0.12% |
| Blackstone Inc. | 2,567,445 | $14,943,000 | 0.11% |